Related Experiment Videos

Progressive multifocal leukoencephalopathy complicating Waldenström's macroglobulinaemia

Christina Ng1, Monica A Slavin, John F Seymour

  • 1Department of Haematology, Peter MacCallum Cancer Institute, Victoria, Australia.

Leukemia & Lymphoma
|December 25, 2003
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML), a rare neurological disorder, can occur in patients with Waldenström's macroglobulinaemia. Early diagnosis is crucial for patients with impaired immunity due to immunosuppressive treatments.

Area of Science:

  • Neurology
  • Virology
  • Immunology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, severe demyelinating disease of the central nervous system.
  • PML is caused by the ubiquitous JC virus (JCV), typically remaining latent in healthy individuals.
  • Immunocompromised states, including hematologic malignancies and post-transplant immunosuppression, significantly increase PML risk.

Observation:

  • This report details a case of PML in a patient with a history of Waldenström's macroglobulinaemia.
  • Waldenström's macroglobulinaemia is a lymphoproliferative disorder that can necessitate immunosuppressive therapies.
  • The patient presented with clinical features suggestive of PML.

Findings:

  • The case highlights a rare complication of PML in the context of Waldenström's macroglobulinaemia.
  • This presentation underscores the risk of opportunistic JCV reactivation under specific iatrogenic immunosuppression.
  • Diagnostic confirmation relies on clinical presentation, neuroimaging, and JCV detection in cerebrospinal fluid.

Implications:

  • The increasing use of potent immunosuppressive agents for lymphoproliferative disorders necessitates heightened clinical vigilance for PML.
  • Physicians must consider PML in immunocompromised patients presenting with neurological deficits, particularly those on long-term immunosuppressive treatments.
  • Prompt diagnosis and management are critical for improving outcomes in patients with PML.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...